The effect of GLP‑1 receptor agonists on improving glucose control and decreasing body weight: results of direct comparative trials and network meta‑analysis
Abstract
Apart from insulin, GLP-1 receptor agonists are the most effective antidiabetics, which decrease body weight and blood pressure and improve blood lipids, in addition to amelioration of glucose control. Numerous options are available within the GLP-1 receptor agonist class that differ to a certain degree.
The aim of this paper is to compare the differences in the efficacy of various GLP-1 receptor agonists in improving glucose control and reducing body weight. Primarily, we focus on comparing the first oral GLP-1 receptor agonist - semaglutide - and injectable GLP-1 receptor agonists.
The results of randomized trials and recently published network meta-analysis show comparable or better efficacy of oral semaglutide in improving glucose control or reducing body weight in contrast with most injectable GLP-1 receptor agonists, except for injectable semaglutide.